XNAS · Healthcare · Biotechnology
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.19 | -0.22 | -15.79% | $0 | ❌ Miss | +0.13% | -5.64% | — |
| 2026-03-19 | Q4 2025 | -0.14 | -0.27 | -92.86% | $0 | ❌ Miss | -2.10% | +4.48% | +19.68% |
| 2025-11-13 |
| Q3 2025 |
| -0.04 |
| -0.30 |
| -650.00% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-27 | Q4 2024 | -0.70 | -0.62 | +11.43% | $0 | ✅ Beat | -0.44% | -7.42% | +19.83% |
| 2024-11-07 | Q3 2024 | -0.64 | -0.72 | -12.50% | $0 | ❌ Miss | +0.61% | -3.07% | -85.25% |
| 2024-08-07 | Q2 2024 | -0.83 | -0.59 | +28.92% | $0 | ✅ Beat | -29.01% | -20.68% | -25.93% |
| 2024-05-08 | Q1 2024 | -0.88 | -0.72 | +18.18% | $0 | ✅ Beat | -0.78% | -9.14% | -22.98% |
| 2024-03-19 | Q4 2023 | -0.83 | -0.84 | -1.20% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.